



Review Article

Can probiotics be used to treat allergic diseases?

Ren-Bin Tang^{a,b,*}, Jia-Kan Chang^{a,b}, Hui-Lan Chen^c

^a Division of Pediatrics, Cheng-Hsin General Hospital, Taipei, Taiwan, ROC

^b National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC

^c Department of Pediatrics, Keelung Hospital, Ministry of Health and Welfare, Keelung, Taiwan, ROC

Received June 4, 2014; accepted August 21, 2014

Abstract

Probiotics are proprietary formulations of specific microorganisms and quantified populations of live bacteria that are intended to confer a health benefit on the host. These different strains and combinations of microorganisms have a wide and varying range of clinical and immunologic capacities that can modify intestinal microbial populations in ways that can benefit the host. The enhanced presence of probiotic bacteria in the intestinal microbiota has been found to correlate with protection against atopy. The prevalence of allergic diseases such as asthma, allergic rhinitis, and atopic dermatitis has increased sharply over the past 2–3 decades in many countries, and allergies are now the most common chronic disease among children throughout the world. In the past few years, probiotics have been advocated for the management of allergic diseases in many parts of the world. So far, probiotics have shown more promise, albeit limited, in the primary prevention of allergic disease rather than in the treatment of established disease.

Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.

Keywords: allergic diseases; allergic rhinitis; asthma; atopic dermatitis; probiotics

1. Introduction

The rapid increase in immune-mediated disorders such as allergic disease is strongly linked to reduced early microbial exposure.^{1,2} The intestine is the body's largest immune organ; most of the antibody-producing cells reside in the intestine.³ The intestinal microbiota represents the body's greatest microbial exposure by a substantial extent, and in part works to provide stimulation of the immune system. The specific composition of the intestinal microbiota may affect the risk of developing allergic disease.^{4–6} This finding provided the foundation for intervention studies designed to modify gut microbial composition for the treatment of allergic disease.

The effects of beneficial bacteria (probiotics) or resistant starches or fiber (prebiotics) that selectively stimulate a limited number of beneficial bacteria have been evaluated in allergy treatment studies.^{7,8} Several reviews have examined the evidence for prebiotics and probiotics in the treatment of allergic disease. However, in the current era of evidence-based medicine, there remains insufficient evidence to formally recommend probiotics for the prevention of allergic diseases or as part of the standard management for any allergic conditions in children.⁹

2. Terminology

An allergy is a hypersensitivity reaction initiated by immunological mechanisms. Such allergies are generally broken down into two groups: an antibody-mediated allergy or a cell-mediated allergy. Hypersensitivity causes objectively reproducible symptoms or signs, initiated by exposure to a defined stimulus at a dose tolerated by healthy individuals.

Conflicts of interest: The authors declare that there are no conflicts of interest related to the subject matter or materials discussed in this article.

* Corresponding author. Dr. Ren-Bin Tang, Division of Pediatrics, Cheng-Hsin General Hospital, 45, Cheng Hsin Street, Pai-Tou, Taipei 112, Taiwan, ROC.

E-mail address: ch9406@chgh.org.com.tw (R.-B. Tang).

Allergens are antigens that cause allergy.¹⁰ These allergens can make contact with the immune system through various routes such as inhalation, ingestion, and skin contact, or enter directly into the body through an insect bite.¹¹ Atopy is a personal or familial tendency, usually in childhood or adolescence, to produce immunoglobulin E (IgE) antibodies in response to ordinary exposure to allergens (usually proteins) and to develop typical symptoms such as asthma, rhinoconjunctivitis, and eczema/dermatitis. However, not all cases are attributable to IgE mechanisms.^{10,12,13} The mechanisms leading to the increased incidence of allergic diseases are not fully understood but are known to involve genetic factors as well as complex interactions between the host and allergen exposure—as well as other environmental stimuli such as the intestinal microbiota and infectious agents.^{14–17}

3. The intestinal immune system

In the healthy gut, the immune system is able to create a balance between the level of protective mucosal immunity and systemic tolerance. Immune homeostasis in the gut develops as a relationship is established between the intestinal microbiota, luminal antigens, and the epithelial barrier.¹⁸ Microbial colonization of the intestine begins after birth, where the sterile gut of the newborn is gradually colonized by environmental bacteria and by contact with the maternal intestinal flora and surroundings and possibly by genetic factors.^{19,20} Exposure to microbial flora early in life allows for a change in the T helper 1 (Th1)/Th2 cytokine balance, favoring a Th1 cell response.²¹ At birth, the immune system of an infant is not fully developed and tends to be directed toward a Th2 phenotype to prevent rejection *in utero*. The Th2 phenotype, however, leads to the stimulated production of IgE by B cells and thus increases the risk for allergic reactions through the activation of mast cells. Microbial stimulation early in life will reverse the Th2 bias and stimulate the development of Th1 phenotype and stimulate the activity of Th3 cells.²² In this manner, their combined action will lead to the production of IgA by B cells. IgA contributes to allergen exclusion and will thereby reduce exposure of the immune system to antigens. Cytokines produced by the Th1 phenotype will also reduce inflammation and stimulate tolerance toward common antigens.²³

4. Mechanisms of action of probiotics in allergic disorders

Although the exact etiology of allergic diseases remains ambiguous, the mechanisms by which microbial exposure affects the development and severity of allergic disease needs to be better understood. The hygiene hypothesis suggests that insufficient or aberrant exposure to environmental microbes is one of the causes of the development of allergy and their associated diseases.^{24–26} As described above, allergic disorders are associated with a shift of the Th1/Th2 cytokine balance leading to activation of Th2 cytokines and the release of interleukin-4 (IL-4), IL-5, and IL-13 as well as IgE production.^{21,27} Probiotics administration dramatically alters the gut

microenvironment by promoting a change in the local microflora and in cytokine secretion, and can potentially modulate the Toll-like receptors and the proteoglycan recognition proteins of enterocytes, leading to the activation of dendritic cells and a Th1 response. The resulting stimulation of Th1 cytokines can suppress Th2 responses.²⁸ Other effects of probiotics that make them suitable for modulation of allergic disease include stimulation of mucosal IgA level as well as allergen-specific B and T cell responses.²⁹ Recent studies suggest that the bacterial–host interaction may induce the expansion of T regulatory cells and the expression of immunomodulatory cytokines such as IL-10 and transforming growth factor-beta; these interactions are very complex and involve networks of genes, Toll-like receptors, signaling molecules, an enhanced intestinal IgA response, and the mechanisms by which probiotics affect innate and adaptive immune responses and patterns of disease.^{30–32}

5. Probiotic strains and effects

Probiotic microorganisms are generally lactic acid bacteria including *Lactobacillus acidophilus*, *Lactobacillus bulgaricus*, *Lactobacillus casei*, *Lactobacillus plantarum*, and *Lactobacillus rhamnosus*. The *Lactobacillus* species possess several important properties such as efficient adherence to intestinal epithelial cells to reduce or prevent colonization of pathogens, competitive growth, and production of metabolites to inhibit or kill pathogens and nonpathogens.³³ However, other bacterial species such as *Bacillus*, *Bifidobacterium* spp., and *Propionibacterium* spp. as probiotic strains have also been described in several commercial products.³⁴ The potential use of *L. casei* strain Shirota has also been described as a probiotic agent for stimulating immune responses and preventing enterobacterial infections,³⁵ and *Lactobacillus* GG is likewise used as an effective oral vaccine for rotaviruses.³⁶ Before the use of a probiotic is considered for hospitalized patients, a careful assessment of risk versus benefit must be made. Additionally, to ensure patient safety, probiotics should be properly handled during administration.³⁷

6. Probiotics' role in allergic disorders

6.1. Probiotics in atopic dermatitis

Numerous animal and *in vitro* studies, as well as several human trials, suggest a beneficial effect of probiotics in allergic diseases. Several randomized studies demonstrated that when *Lactobacillus* GG or placebo was given to pregnant mothers with a strong family history of eczema, allergic rhinitis, or asthma and to their infants for the first 6 months after delivery, the frequency of developing atopic dermatitis in the offspring was reduced in 2 years, 4 years, and 7 years by 50%, 44%, and 36%, respectively.^{38,39} However, after Lee et al⁴⁰ searched PubMed and the Cochrane database in 21 trials for review and quality assessment of probiotics in the prevention and treatment of pediatric atopic dermatitis, current evidence suggested that probiotics had a superior efficacy in

prevention rather than treatment of the condition. Probiotics may affect early development of immune tolerance during the 1st year of life, explaining their potential effect in children with atopic dermatitis.⁴¹ However, the European Society of Paediatric Gastroenterology, Hepatology, and Nutrition Committee on Nutrition is concerned that the available data are not sufficient to support the safety of probiotics in healthy newborn and very young infants with immature defense systems, infants with immunocompromised systems, premature infants, and infants with congenital heart disease.⁴²

6.2. Probiotics in asthma

A small number of studies exist that attempt to address the efficacy of probiotic supplementation in the treatment or prevention of asthma. One study using fermented milk containing *L. casei* and studying its effect on the number of episodes of asthma and allergic rhinitis found no statistical difference between intervention and control groups of asthmatic children. However, the number of rhinitis episodes was lower in the probiotic group, leading the authors to conclude that *L. casei* may benefit children with allergic rhinitis but not asthmatic children.^{21,43} No primary prevention study has been able to demonstrate an effect of probiotic supplementation for asthma in humans.⁴⁴

6.3. Probiotics in allergic rhinitis

Reports on the efficacy of probiotics in treating allergic rhinitis are conflicting. Giovannini et al⁴³ revealed that *L. casei* reduced the number of rhinitis episodes in 64 preschool children with allergic rhinitis. However, another trial showed that patients treated with *Lactobacillus* GG during the birch pollen season who were allergic to birch pollen and apple food demonstrated neither reduction of symptom score, nor any lesser sensitization to birch pollen and apple after probiotics supplementation.⁴⁵ Recently, data from the PubMed database and published studies indicate that probiotic intake improved the quality of life score in patients with allergic rhinitis. There was no significant change in blood or immunologic parameters in the probiotic group. This suggests that probiotics may be useful in allergic rhinitis, but the present data are not sufficient to allow for any treatment recommendations.^{46,47}

6.4. Probiotics in food allergy

Recent studies suggest that probiotics may have a role in the treatment of food allergy by maintaining the intestinal epithelial barrier integrity, suppressing intestinal inflammatory responses, and inducing mucosal IgA production and tolerogenic immune responses.^{48,49} However, Hol et al⁵⁰ found no effect of *L. casei* CRL431 and *B. lactis* Bb-12 supplementation for 12 months on the acquisition of tolerance in 119 infants with cow's milk allergy. Another study on children with egg, peanut, or cow's milk allergy who were treated with a probiotic mix (predominantly *Lactobacillus* spp. and *Bifidobacterium* spp.) for 3 months showed that the treatment did not influence

sensitization or *ex vivo* immune responses. This would further indicate that the evidence as to whether probiotics can induce tolerance in allergy is currently lacking.⁵¹

In conclusion, probiotics may have a potential role in the prevention and treatment of atopic dermatitis, but studies to date have not been conclusive. Currently, there is no role for probiotic therapy in the treatment of asthma. A World Allergy Organization Special Committee on Food Allergy and Nutrition reviewed the evidence regarding the use of probiotics for the prevention and treatment of allergy. The committee concluded that probiotics do not have an established role in the prevention or treatment of allergy.¹² The contradictory results of the studies on the efficacy of probiotics in the prevention and treatment of allergy may be attributable to the great heterogeneity of strains, duration of therapy, and doses used. Even if there are promising data on the treatment of atopic dermatitis, little is known about the efficacy of probiotics for respiratory allergic symptoms and food allergy.^{52–54} The literature associated with probiotic consists primarily of reviews, and few of them are systematic; meta-analyses are rare. Explanations for the varied results between studies include host factors, environmental factors, individual microbiota, patient diet of prebiotic substances, and treatment with antibiotics.⁵⁵ Future studies will be important to better understand and refine the current knowledge base for potential use of probiotics in allergy.

References

1. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. *N Engl J Med* 2002;**347**:911–20.
2. Williams H, Stewart A, von Mutius E, Cookson W, Anderson HR, International Study of Asthma and Allergies in Childhood (ISAAC) Phase One and Three Study Groups. Is eczema really on the increase worldwide? *J Allergy Clin Immunol* 2008;**121**:947–54.
3. Brandtzaeg P. Current understanding of gastrointestinal immunoregulation and its relation to food allergy. *Ann N Y Acad Sci* 2002;**964**:13–45.
4. Penders J, Stobberingh EE, van den Brandt PA, Thijs C. The role of the intestinal microbiota in the development of atopic disorders. *Allergy* 2007;**62**:1223–36.
5. Wang M, Karlsson C, Olsson C, Adlerberth I, Wold AE, Strachan DP, et al. Reduced diversity in the early fecal microbiota of infants with atopic eczema. *J Allergy Clin Immunol* 2008;**121**:129–34.
6. Gore C, Munro K, Lay C, Bibiloni R, Morris J, Woodcock A, et al. *Bifidobacterium pseudocatenulatum* is associated with atopic eczema: a nested case-control study investigating the fecal microbiota of infants. *J Allergy Clin Immunol* 2008;**121**:135–40.
7. Tang ML, Lahtinen SJ, Boyle RJ. Probiotics and prebiotics: clinical effects in allergic disease. *Curr Opin Pediatr* 2010;**22**:626–34.
8. Nowak-Wegrzyn A, Muraro A. Food allergy therapy: is a cure within reach? *Pediatr Clin North Am* 2011;**58**:511–30.
9. Yao TC, Chang CJ, Hsu YH, Huang JL. Probiotics for allergic diseases: realities and myths. *Pediatr Allergy Immunol* 2010;**21**:900–19.
10. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. *J Allergy Clin Immunol* 2004;**113**:832–6.
11. Weiner HL, Da Cunha AP, Quintana F, Wu H. Oral tolerance. *Immunol Rev* 2011;**241**:241–59.
12. Fiocchi A, Burks W, Bahna SL, Bielory L, Boyle RJ, Cocco R, et al. Clinical use of probiotics in pediatric allergy (CUPPA): a World Allergy Organization position paper. *World Allergy Org J* 2012;**5**:148–67.

13. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. *J Allergy Clin Immunol* 2010;**126**:466–76.
14. Chiang CH, Lin MW, Chung MY, Yang UC. The association between the IL-4, ADR β 2 and ADAM 33 gene polymorphisms and asthma in the Taiwanese population. *J Chin Med Assoc* 2012;**75**:635–43.
15. Torgerson DG, Ampleford EJ, Chiu GY, Gauderman WJ, Gignoux CR, Graves PE, et al., Mexico City Childhood Asthma Study (MCAAS). Meta-analysis of genomewide association studies of asthma in ethnically diverse North American populations. *Nat Genet* 2011;**43**:887–92.
16. Priault G, Nagler-Anderson C. Mucosal immunity and allergic responses: lack of regulation and/or lack of microbial stimulation? *Immunol Rev* 2005;**206**:204–18.
17. Chen CJ, Hung MC, Kuo KL, Chung JL, Wu KG, Hwang BT, et al. The Role of Eosinophil cationic protein in patients with *Mycoplasma pneumoniae* infection. *J Chin Med Assoc* 2008;**71**:37–9.
18. Iweala OI, Nagler CR. Immune privilege in the gut: the establishment and maintenance of non-responsiveness to dietary antigens and commensal flora. *Immunol Rev* 2006;**213**:82–100.
19. Gerrard JW, Vickers P, Gerrard CD. The familial incidence of allergic disease. *Ann Allergy* 1976;**36**:10–5.
20. Von Mutius E, Braun-Fahrlander C, Schierl R, Riedler J, Ehlermann S, Maisch S, et al. Exposure to endotoxin or other bacterial components might protect against the development of atopy. *Clin Exp Allergy* 2000;**30**:1230–4.
21. Michail S. The role of probiotics in allergic diseases. *Allergy Asthma Clin Immunol* 2009;**5**:5.
22. von der Weid T, Bulliard C, Schiffrin EJ. Induction by a lactic acid bacterium of a population of CD4 (+) T cells with low proliferative capacity that produce transforming growth factor beta and interleukin-10. *Clin Diagn Lab Immunol* 2001;**8**:695–701.
23. Kirjavainen PV, Gibson GR. Healthy gut microflora and allergy: factors influencing development of the microbiota. *Ann Med* 1999;**31**:288–92.
24. Strachan DP. Family size, infection and atopy: the first decade of the “hygiene hypothesis”. *Thorax* 2000;**55**:S2–10.
25. Noverr MC, Huffnagle GB. The ‘microflora hypothesis’ of allergic diseases. *Clin Exp Allergy* 2005;**35**:1511–20.
26. Tang RB. Risk factors associated with the development of asthma. *J Chin Med Assoc* 2005;**68**:199–201.
27. Tang RB, Chen SJ. Soluble interleukin 2 receptor and interleukin 4 in sera of asthmatic children before and after a prednisolone course. *Ann Allergy Asthma Immunol* 2001;**86**:314–7.
28. Winkler P, Ghadimi D, Schrezenmeir J, Kraehenbuhl JP. Molecular and cellular basis of microflora–host interactions. *J Nutr* 2007;**137** (Suppl 2):S756–72.
29. Toh ZQ, Anzela A, Tang ML, Licciardi PV. Probiotic therapy as a novel approach for allergic disease. *Front Pharmacol* 2012;**3**:171.
30. McLoughlin RM, Mills KH. Influence of gastrointestinal commensal bacteria on the immune responses that mediate allergy and asthma. *J Allergy Clin Immunol* 2011;**127**:1097–107.
31. Gourbeyre P, Denery S, Bodinier M. Probiotics, prebiotics, and synbiotics: impact on the gut immune system and allergic reactions. *J Leukoc Biol* 2011;**89**:685–95.
32. D'Arienzo R, Maurano F, Lavermicocca P, Ricca E, Rossi M. Modulation of the immune response by probiotic strains in a mouse model of gluten sensitivity. *Cytokine* 2009;**48**:254–9.
33. De Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. *Adv Biochem Eng Biotechnol* 2008;**111**:1–66.
34. Chukeatirote E. Potential use of probiotics Songklanakarin. *J Sci Technol* 2003;**25**:275–82.
35. Matsuzaki T. Immunomodulation by treatment with *Lactobacillus casei* strain Shirota. *Int J Food Microbiol* 1998 **26**:41:133–40.
36. Isolauri E, Joensuu J, Suomalainen H, Luomala M, Vesikari T. Improved immunogenicity of oral D α RRV reassortant rotavirus vaccine by *Lactobacillus casei* GG. *Vaccine* 1995;**13**:310–2.
37. Venugopalan V, Shriner K, Wong-Beringer A. Regulatory oversight and safety of probiotic use. *Emerg Infect Dis* 2010;**16**:1661–5.
38. Kalliomaki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease. 4-year follow-up of a randomized placebo-controlled trial. *Lancet* 2003;**361**:1869–71.
39. Kalliomaki M, Salminen S, Poussa T, Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. *J Allergy Clin Immunol* 2007;**119**:1019–21.
40. Lee J, Seto D, Bielory L. Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. *J Allergy Clin Immunol* 2008;**121**:116–21.
41. Barclay L. Benefits of probiotics reviewed. *Am Fam Physician* 2008;**78**:1073–8.
42. Agostoni C, Axelsson I, Braegger C, Goulet O, Koletzko B, Michaelsen KF, et al. Probiotic bacteria in dietetic products for infants: a commentary by the ESPGHAN committee on nutrition. *J Pediatr Gastroenterol Nutr* 2004;**38**:365–74.
43. Giovannini M, Agostoni C, Riva E, Salvini F, Ruscitto A, Zuccotti GV, et al. A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing *Lactobacillus casei* in pre-school children with allergic asthma and/or rhinitis. *Pediatr Res* 2007;**62**:215–20.
44. Vliagoftis H, Kouranos VD, Betsi GI, Falagas ME. Probiotics for the treatment of allergic rhinitis and asthma: systematic review of randomized controlled trials. *Ann Allergy Asthma Immunol* 2008;**101**:570–9.
45. Helin T, Haahtela S, Haahtela T. No effect of oral treatment with an intestinal bacterial strain, *Lactobacillus rhamnosus* (ATCC 53103), on birch-pollen allergy: a placebo-controlled double-blind study. *Allergy* 2002;**57**:243–6.
46. Yang G, Liu ZG, Yang PC. Treatment of allergic rhinitis with probiotics: an alternative approach. *N Am J Med Sci* 2013;**5**:465–8.
47. Das RR, Singh M, Shafiq N. Probiotics in treatment of allergic rhinitis. *World Allergy Organ J* 2010;**3**:239–44.
48. del Giudice MM, Leonardi S, Maiello N, Brunese FP. Food allergy and probiotics in childhood. *J Clin Gastroenterol* 2010;**44**:S22–5.
49. Ismai IH, Licciardi PV, Tang MLK. Probiotic effects in allergic disease. *J Paediatr Child Health* 2013;**49**:709–15.
50. Hol J, van Leer EH, Elink-Schuurman BE, de Ruiter LF, Samsom JN, Hop W, et al. The acquisition of tolerance toward cow's milk through probiotic supplementation: a randomized, controlled trial. *J Allergy Clin Immunol* 2008;**121**:1448–54.
51. Castellazzi AM, Valsecchi C, Caimmi S, Licari A, Marseglia A, Leoni MC, et al. Probiotics and food allergy. *Ital J Pediatr* 2013;**39**:47.
52. Flinterman AE, Knol EF, van Ieperen-van Dijk AG, Timmerman HM, Knulst AC, Bruijnzeel-Koomen CA, et al. Probiotics have a different immunomodulatory potential in vitro versus ex vivo upon oral administration in children with food allergy. *Int Arch Allergy Immunol* 2007;**143**:237–44.
53. Kuitunen M. Probiotics and prebiotics in preventing food allergy and eczema. *Curr Opin Allergy Clin Immunol* 2013;**13**:280–6.
54. Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Judel M, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. *J Allergy Clin Immunol* 2013;**131**:1288–96.
55. Prescott SL, Bjorksten B. Probiotics for the prevention or treatment of allergic diseases. *J Allergy Clin Immunol* 2007;**120**:255–62.